<p>Covering a wide variety of topics, with a special focus on Novartis as one of the best examples of a learning organisation in pharma. On cultures of innovation, 'unbossing', decision making and measuring what matters John can be found on LinkedIn: https://www.linkedin.com/in/john-tsai-md-ab398b4/ or contacted by email at john_tsai.office at novartis.com</p>

Covering a wide variety of topics, with a special focus on Novartis as one of the best examples of a learning organisation in pharma. On cultures of innovation, 'unbossing', decision making and measuring what matters John can be found on LinkedIn: https://www.linkedin.com/in/john-tsai-md-ab398b4/ or contacted by email at john_tsai.office at novartis.com

IDEA Collider | John Tsai, MD

IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare.

Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking.

Questions We Explore

* What is asymmetric learning, and how does it fuel pharma innovation?
* Why do some organizations outpace others—and what can we learn from them?
* How can we overcome barriers to meaningful progress in healthcare?
* What’s broken in traditional innovation models—and how do we fix it?


🎧 Listen and subscribe on all major platforms.

Business

Science

Marketing

Management

Life Sciences

IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace others—and what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * What’s broken in traditional innovation models—and how do we fix it? 🎧 Listen and subscribe on all major platforms.

IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare.

Each episode dives into how organizations can make smarter decisions earlier, reimagine R&amp;D, and unlock competitive advantage through differentiated thinking.

Questions We Explore

* What is asymmetric learning, and how does it fuel pharma innovation?
* Why do some organizations outpace others—and what can we learn from them?
* How can we overcome barriers to meaningful progress in healthcare?
* What’s broken in traditional innovation models—and how do we fix it?


🎧 Listen and subscribe on all major platforms.

Share IDEA Collider | John Tsai, MD

Sign up to save your podcasts

IDEA Collider | John Tsai, MD

IDEA Collider | John Tsai, MD

More shows like IDEA Collider: Innovation & Asymmetric Learning in Pharma

Odd Lots

The Daily

The Readout Loud

FT News Briefing

The Journal.

BioCentury This Week

People I (Mostly) Admire

The Ezra Klein Show

Biotech Hangout

The Rest Is Politics

The Top Line

The Rest Is Politics: US

The BioCentury Show

The Economics Show

Cures & Capital